Breast Cancer Clinical Trials in Paris
17 recruitingParis, France
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Not Applicable
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Breast Cancer
Institut Claudius Regaud120 enrolled25 locationsNCT05378204
Recruiting
Phase 3
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Breast Cancer
AstraZeneca100 enrolled40 locationsNCT07205822
Recruiting
Phase 3
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.
Breast Cancer
Institut Curie158 enrolled3 locationsNCT05439005
Recruiting
Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie
Breast CancerLung Cancer
Institut Curie200 enrolled1 locationNCT07357311
Recruiting
REBECCA Real-world Early BrEast CanCer mAnagement
Breast Cancer
AstraZeneca126 enrolled44 locationsNCT06856343
Recruiting
Not Applicable
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast CancerLung CancerComorbidities and Coexisting Conditions
Institut Bergonié720 enrolled10 locationsNCT05720910
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Not Applicable
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
Breast CancerCognitive Dysfunction
Centre Francois Baclesse300 enrolled25 locationsNCT06027632
Recruiting
Not Applicable
Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request
Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle264 enrolled9 locationsNCT06415266
Recruiting
Not Applicable
Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
Breast CancerCapsular Contracture Associated With Breast Implant
Institut du Cancer de Montpellier - Val d'Aurelle250 enrolled9 locationsNCT04342546
Recruiting
FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
Breast Cancer
Centre Hospitalier Universitaire de Besancon4,500 enrolled5 locationsNCT06185569